版本:
中国

BRIEF-FDA puts clinical hold on Concert Pharma's hair loss drug

May 17 Concert Pharmaceuticals Inc:

* Concert Pharmaceuticals announces clinical hold on ctp-543 phase 2A trial

* Concert Pharmaceuticals says FDA requested review of recently completed non-clinical studies

* Concert Pharmaceuticals - FDA requested review of recently completed non-clinical studies

* Concert Pharmaceuticals - FDA did not cite a safety concern

* Concert Pharmaceuticals - at request of FDA, company intends to submit requested non-clinical study reports promptly

* Concert Pharmaceuticals - FDA intend to review additional non-clinical data as support for one-year dosing duration as planned in phase 2a trial

* Concert Pharmaceuticals - received notice from U.S. FDA that its ctp-543 phase 2a clinical trial for alopecia areata has been placed on clinical hold Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐